Glecaprevir and pibrentasvir

  • Part D specialty tier in 77% of formularies (2026Q3)
  • Mavyret

Therapy management checklist

Screening, baseline and ongoing monitoring with the label's stated frequency, hold and discontinue criteria, and counseling points, each quoted from the FDA label.

Loading the therapy management checklist…

Storage and cold chain

Glecaprevir and pibrentasvir: storage and handling

Freezing
Not addressed
Room temperature
No allowance stated
Back into the refrigerator
Not addressed
Light
Not addressed
Shaking
Not addressed

Temperature excursion helper

Answers only from this label's storage statements. It does not judge whether a product is still usable beyond what the label states.

The label does not state a room-temperature allowance for this product.

Entered: 1 day at up to 77°F (25°C).

Contact the manufacturer at 1-800-633-9110 (the number printed on the label) about this product.

Where the label prints this number
For more information go to www.MAVYRET.com or call 1-800-633-9110.
All storage statements on the label (2)
  • Store at or below 30°C (86°F).
  • Store MAVYRET at or below 86°F (30°C).

FDA label version 201, effective June 25, 2025. DailyMed

Dosing and titration calendar

Built only from the schedules the label states (loading, titration, day schedules, cycles and weight bands). Steps the label states in words the calendar cannot place are shown, not guessed.

Loading dosing schedules…

Medicare Part D coverage

67%of plans list it
97%of those: prior authorization
0%step therapy
52%quantity limit
95%specialty tier

5,496 Part D plans, CMS formulary files 2026Q3. Look up tier, PA, step therapy and quantity limits by plan

Patient assistance

Independent foundations and the full directory (checked 2026-11-06). Eligibility and amounts are set by each program; open its page for them.

For licensed clinicians. Use with clinical judgment. Statements are quoted from the FDA label; confirm against the label for the product you are using.